Search

everythinglearnresearchcommunity

for

Search:↓

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

A 19-year-old with NW2-2.5 hair loss is starting finasteride soon, considering low dosages of 0.25mg daily or 0.5mg 3-5 times a week. They are also using derma stamping, ketoconazole shampoo, ACV washes, and various oils to maintain hair quality and reduce scalp itch.

MaximusDurkimus shares experience with 0.25mg Finasteride, Minoxidil-induced lupus, and less than 10mg RU58841 for hair loss. Plans to try 0.025% topical Finasteride with 5% Stemoxydine and possibly Tretinoin, Fluridil, or CB-03-01 in the future.

Scalp irritation from homemade topical finasteride may be caused by isopropyl alcohol. Alternatives suggested include using ethanol or everclear with distilled water.

The conversation is about a 9-month hair regrowth progress using Dutasteride 0.5mg and Oral Minoxidil 2.5mg daily. Users commented on the improved hair quality and requested to see the hairline.

A 22-year-old has been using dutasteride (0.5 mg daily) for over a year but is experiencing increased hair shedding, scalp inflammation, and burning, and cannot use minoxidil due to side effects. Suggestions include consulting a dermatologist, trying oral minoxidil, microneedling, rosemary oil, caffeine shampoo, and considering other treatments like PRP or red light therapy.

The conversation is about a user's positive hair regrowth results using oral Dutasteride (DUT) and topical Minoxidil (MIN), with occasional derma rolling. The user experienced initial shedding but saw improvement after 8 months, and others discussed the use of Finasteride (FIN) and Tretinoin to enhance results.

The user shared progress pictures showing hair thickening after 3 months of using a topical treatment of 0.3/6% finasteride/minoxidil. They also maintained their hair health with 1% Nizoral twice a week and dermastamping every 1.5-2 weeks.

The conversation discusses hair loss treatments including finasteride, minoxidil, derma rolling, and tretinoin, with the user showing progress after five months. Tretinoin is mentioned to enhance the effectiveness of minoxidil.

A user's progress with treating hair loss by using finasteride (1mg MWF) and minoxidil (5% once daily), occasionally using ketoconazole gel, and dermarolling 1.5mm every two weeks; other users' responses are positive and ask for more information about the treatment regimen.

A user is seeking advice on adding dutasteride to their finasteride regimen to stop DHT-related scalp itch. They have tried selenium sulfide and ketoconazole shampoos with temporary success.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user has been using 1mg Finasteride and 5% topical Minoxidil for 9 months with little improvement and has recently added microneedling, showing slight progress. The new protocol includes switching to 5mg oral Minoxidil, continuing microneedling, and adding Anagenil Complex, while seeking advice on whether to stop topical Minoxidil and the effectiveness of Anagenil Complex.

The conversation is about a user's progress in treating diffuse hair thinning using a topical regimen including finasteride, minoxidil, ketoconazole, microneedling, saw palmetto, collagen, and vitamins, along with lifestyle changes. The user plans to switch from topical to oral finasteride for potentially better results.

Switching from finasteride to dutasteride worsened hair loss and caused a burning sensation. Users suggest sticking with finasteride, using ketoconazole shampoo, and consulting a dermatologist.

A user shared their 20-week progress using topical minoxidil (5%) and finasteride (0.1%) with a 1mm dermastamp, showing significant hair regrowth from NW5 to between NW3V and NW4. They experienced no side effects and plan to update at 12 months.

A user is experiencing severe hair loss, diagnosed with seborrheic dermatitis, and is using Ketoconazole and beclomethasone. They are concerned about potential female pattern baldness and are seeking reassurance and advice.

Topical 1% cetirizine is more effective for hair growth than 10 mg oral cetirizine. It can be ordered online from specific hair loss companies.

A 59-year-old man with significant hair loss has seen some improvement, including reversal of Retrograde Alopecia and darkening of hair, after switching to RU58841 and a new minoxidil base solution with additional ingredients. He also changed from a derma roller to a derma stamp for application.

User started oral finasteride 0.33mg daily and later made a topical solution with cetirizine and stemoxydine. They experienced hair growth progress after 8-9 months and discussed factors affecting their results.

The conversation discusses hair loss treatment progress over five years using 0.5mg dutasteride daily and 5mg oral minoxidil daily. Users comment on the difficulty of assessing progress due to lighting and hair length differences, but note the hair looks good in both photos.

User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.

The conversation discusses hair loss treatment using daily topical minoxidil and finasteride, daily 0.5mm dermarolling before application, and 2% ketoconazole shampoo three times a week. Users believe dermarolling enhances the absorption of the treatments and expect significant improvements over time.

A 33-year-old male has been using topical dutasteride and minoxidil twice daily, along with a 0.25 mm derma roller every five days, and is experiencing hair shedding but seeing progress. Some users suspect a hair transplant, while others praise the results.

A user's progress with treating their hair loss, which consists of using Dutasteride, RU58841, Stemoxydine and Tretinoin 0.05% over the past three months.

A 21-year-old is using 5mg Minoxidil, 1mg Dutasteride, Nizoral, and occasional microneedling for hair loss, seeing improvement on the left side of the scalp. They stopped microneedling due to scalp inflammation and are awaiting a dermatologist appointment.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

The user has been experiencing hair loss for over 5 years and is currently using a topical treatment of finasteride, minoxidil, and tretinoin, along with derma rolling and a hair growth oil. They have previously tried oral finasteride, pyrithione zinc, RU58841, and dutasteride, but are seeking advice on whether to retry dutasteride or find a more reliable source for RU58841 due to ongoing hair density loss.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.